Plos One 1

Mapping evidence on cryptococcal antigen infection among HIV-infected 2 persons in sub-Saharan Africa- A Scoping Review Protocol 3

- Khululiwe Dlamini¹, Boitumelo Moetlhoa¹, Astrid Turner¹, Kuhlula Maluleke¹ and 4
- Tivani Mashamba-Thompson² 5

6

- ¹School of Health Systems and Public Health, Faculty of Health Sciences, University 7 of Pretoria, Pretoria, South Africa
- 8
- ²Faculty of Health Sciences, University of Pretoria, South Africa 9

10

11 Corresponding author: Boitumelo Moetlhoa

12

¹School of Health Systems of Public Health, Faculty of Health Sciences, University of 13 Pretoria, South Africa 14

15

16 Email: <u>u22029992@tuks.co.za</u>

17

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

18 Abstract

19

Introduction: Infections of the central nervous system are a considerable basis of 20 mortality in people living with Human immunodeficiency virus (HIV), with progression 21 to cryptococcal meningitis documented at around 15% of HIV-associated mortality 22 globally, with nearly three-quarters occurring in the sub-Saharan Africa. Discoveries 23 from previous studies preluded that mortality amid cryptococcal antigen (CrAg) 24 positive persisted to be elevated than in CrAg negative persons. One feasible 25 interpretation of this could be due to undiagnosed cryptococcus. Laboratory 26 investigations towards prompt identification of cryptococcal disease prior to 27 cryptococcal meningitis has progressed to point-of-care testing with high sensitivity 28 29 and specificity as seen with the CrAg lateral flow assay screening to expedite treatment. The aim of the study is to map and translate evidence on CrAg infection 30 among HIV-infected persons in sub-Saharan Africa (SSA). 31

Methodology: The proposed scoping review will be conducted using guidelines 32 proposed by Arksey and O'Malley methodological framework and Levac et al 33 advanced method. It will be guided by the Preferred Reporting Items for Systematic 34 Reviews and Meta-Analysis for Scoping Reviews. A comprehensive literature search 35 of studies published from the first relevant publication to 2022 will be conducted on 36 multiple electronic databases. Additional sources (grey literature) will also be 37 searched. The search strategy will be generated and implemented by the principal 38 investigator with assistance from a subject specialist, and an information specialist. 39 40 Two reviewers will screen eligible studies. The screening will be guided by an inclusion and exclusion criteria. The mixed method appraisal tool (MMAT) version 2018 will be 41 used to appraise the quality of the empirical studies. 42

Discussion: The proposed scoping review will map and translate evidence on CrAg infection among HIV-infected persons in sub-Saharan Africa. Synthesising and sharing recent evidence in this area has potential to help guide future research and interventions aimed at improving the management of CrAg infection among HIVinfected persons in sub-Saharan Africa and other high HIV- burdened settings.

Keywords: Human immunodeficiency virus, cryptococcal antigen, sub-Saharan
Africa

50 Introduction

Cryptococcal disease is a paramount cause of illness in people living with HIV/AIDS 51 and has major consequences if left undiagnosed and untreated. An approach to 52 identifying risk of progression to disease is necessary to guide CrAg screening in the 53 distribution of resources particularly in resource-limited settings when supervising 54 people demonstrating advanced HIV disease. Updated guidelines are required to 55 provide recommendations on approach to detection, diagnosis and treatment. These 56 guidelines also include strategies on preventing invasive illness and potential impact 57 with antiretroviral therapy (ART). When cryptococcal disease is suspected, the CrAg 58 point-of-care (POC) testing is conducted to enable prompt treatment before the 59 progression to cryptococcal meningitis (CM). CM is the most common appearance of 60 the infection and a contributing factor to the morbidity and mortality in the SSA. 61 Mortality is further increased through the immediate initiation of ART in people living 62 with HIV (PLHIV) that have been diagnosed with CM. The guidelines recommended 63 by the World Health Organisation (WHO), is to delay ART by 4–6 weeks from the 64 initiation of antifungal treatment (1, 2). 65

Discovering the estimates of incidence and prevalence of HIV-related diseases 66 specially in cryptococcal infection has been continuous in studies globally (3-6), 67 despite the advancement of HIV management and medicine. The global burden 68 estimates have important purpose in recommended guidelines for prevention 69 strategies required for treatment. Studies were conducted on "the prevalence of 70 cryptococcal infection among HIV-persons with a CD4 cell count of less than 100 71 72 cells/µL" however, the clinical characteristics of PLHIV, with the progression to CM proportional with elevated CD4 cell counts (101-200 cells/µL), would contribute 73 74 discernment into the role of the immune response to the pathogenesis of CM. This enables customization of applicable treatment interventions for cryptococcosis (1). 75 Identified patients begin pre-emptive therapy with a high concentrated dosage of 76 fluconazole to inhibit development of severe disease (1, 7, 8). A CD4 cell count is a 77 78 necessary tool in aiding decision-makers in clinical management (9). A CD4 cell count of less than 200 cells/µL is regarded a threshold for potential morbidity (10). The WHO 79 80 recommends screening for CrAg in PLHIV, followed by pre-emptive antifungal treatment for a positive screening, to prevent progression to CM. This 81

recommendation is for adults and adolescents living with HIV before the initiation or 82 re-initiation of ART therapy (2). One study publicized that in Africa, the cryptococcosis-83 associated immune reconstitution inflammatory syndrome (IRIS) is dangerous with 27-84 83% reported mortalities, this would be due to undiagnosed cryptococcosis. Additional 85 studies would be necessary to further understand the perseverance of high mortality 86 in the context of establishing appropriate strategies in screening for CM within routine 87 testing (7). Laboratory investigations towards early detection of cryptococcal disease 88 prior to CM has progressed to POC testing with high sensitivity and specificity as seen 89 90 with the CrAg lateral flow assay (CrAg LFA) screening to expedite treatment (9, 11), therefore the level of evidence to validate clinic-based CrAg LFA testing in sub-91 Saharan Africa (SSA) is not clear (12). The proposed scoping review aims to 92 systematically map evidence on CrAg infection among HIV-infected persons in sub-93 Saharan Africa. It is anticipated that findings from this study will contribute evidence 94 to propose improved management of CrAg infections within healthcare in SSA. 95

96

97 Methodology

The scoping review will be performed using guidelines proposed by Arksey and 98 O'Malley (14) methodological framework and Levac et al advanced method (15) and 99 guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analysis 100 for Scoping Reviews (PRISMA-ScR) (16, 17). The five stages of Arksey and O'Malley 101 framework that will be used to perform this scoping review are: i) identifying the 102 research question ii) identifying relevant studies iii) eligible study selection iv) charting 103 the data and v) collating, summarising and reporting the results. This scoping review 104 will not incorporate stage six involving stakeholders' consultation. 105

i. Identifying the research question

107 The research question is: What is the level of evidence on CrAg infection among HIV-108 infected persons in SSA? To Refine the research question for the scoping review we 109 will use the Population, Concept, Context (PCC) nomenclature summarized in table 1 110 below.

111

Table 1: PCC framework for refining the research question

Population	HIV-infected persons all infected people
Concept	CrAg infection Opportunistic fungal agent resulting in HIV-related infection (18)
Context	sub-Saharan Africa

112

113 ii. Identifying relevant studies

114 Comprehensive literature searches of studies published from the first relevant 115 publication to 2022 will be conducted on the following electronic databases from 116 Scopus, PubMed, and EBSCO host (MEDLINE, Cumulative Index to Nursing and 117 Allied Health Literature (CINAHL). Additionally, we will look at grey literature (university dissertations and thesis), government and international organisations such as WHO reports to determine more sources of information that have not been arranged by electronic databases. We will manually search for references cited in the included articles. The English language will be applied.

A comprehensive literature search strategy combining terms will be done in three separate searches: "HIV" "PLHIV" "HIV infected persons" "advance HIV disease" "HIV related disease", "Cryptococcal" "Cryptococcus" "Cryptococcosis" "Cryptococcal antigen" "Cryptococcal antigen infection" "CrAg" "CrAg screening" "Cryptococcal meningitis" "Meningitis", and "Sub-Saharan Africa" "SSA".

The search strategy will be created and implemented by the principal investigator (PI) with assistance from a subject specialist, and an information specialist (university librarian). Each database search will be on record to show the following: date of search, electronic database, keywords/MeSH terms, and the number of recovered studies. A pilot search was conducted on one of the electronic databases and the findings are documented in table 2 below. To confirm accurate use of terminology, keywords may be edited to ensure database search suitability.

1	21	
т.	.54	

Date of	Electronic	Keywords/MeSH terms	Number of
search	Database		hits
05/10/2022	PubMed	HIV: "hiv"[MeSH Terms] OR "hiv"[All Fields] cryptococcal: "cryptococcus"[MeSH Terms] OR "cryptococcus"[All Fields] OR "cryptococcal"[All Fields] infection: "infect"[All Fields] OR "infectability"[All Fields] OR "infectable"[All Fields] OR "infectant"[All Fields] OR "infected"[All Fields] OR "infected"[All Fields] OR "infecteds"[All Fields] OR "infectibility"[All Fields] OR "infectible"[All Fields] OR "infectible"[All Fields] OR "infecting"[All Fields] OR "infecting"[All Fields] OR "infections"[All Fields] OR "infections"[All Fields] OR	485

"infection"[All Fields] OR	
"infective"[All Fields] OR	
"infectiveness"[All Fields] OR	
"infectives"[All Fields] OR	
"infectivities"[All Fields] OR	
"infects"[All Fields] OR	
"pathogenicity"[Subheading] OR	
"pathogenicity"[All Fields] OR	
"infectivity"[All Fields]	
sub-Saharan Africa: "africa south	
of the sahara"[MeSH Terms] OR	
("africa"[All Fields] AND "south"[All	
Fields] AND "sahara"[All Fields])	
OR "africa south of the sahara"[All	
Fields] OR ("sub"[All Fields] AND	
"saharan"[All Fields] AND	
"africa"[All Fields]) OR "sub	
saharan africa"[All Fields]	

135

Eligible study selection 136 iii.

The following criteria will be used to select relevant studies: 137

Inclusion criteria 138

- Studies reporting evidence of HIV/AIDS patients 139 \checkmark
- ✓ Studies conducted among adults and children in SSA 140
- ✓ Studies reporting evidence on CM diagnosis from CSF sample and CrAg 141
- infection from whole blood, serum and plasma (CSF sample has the highest 142 diagnostic value irrespective of the blood sample result) 143
- \checkmark Studies reporting evidence on estimates of the incidence, prevalence, and 144 mortality of cryptococcal infection and CM 145
- ✓ Studies reporting evidence on patients with historical cryptococcosis or overt 146 clinical CM 147
- Exclusion criteria 148
- The following criteria will be used to exclude studies: 149
- ✓ Studies reporting evidence other than whole blood, CSF sample, serum and 150 plasma 151
- ✓ Studies reporting evidence of patients receiving antifungal treatment 152

153 ✓ Studies that report evidence of disease unrelated to CM (bacterial or viral
 154 meningitis, tuberculous meningitis, protozoan infections, and space-occupying
 155 cerebral oedema lesion e.g. tuberculoma, hydrocephalus or CNS malignancy)

- 156 ✓ Studies reporting evidence on primary studies conducted outside SSA
- 157 ✓ Studies that do not specify CM diagnosis, CrAg infection, or record of test
 158 performed
- 159 ✓ Review articles

Following the electronic database search, the eligible studies will be transferred to 160 Endnote, a citation management software. The PI will work independently to screen 161 162 titles using the inclusion and exclusion criteria guide. The PI, with the assistance of an independent co-screener will screen the abstracts. Disagreements between the two 163 screeners will be settled by a discussion until unanimity is reached. Screening of full 164 article will be conducted by the same set of screeners. Any discrepancies that emerge 165 after screening full articles will be settled by introducing a third screener. The degree 166 of agreement amongst the screeners after full article screening will be established 167 through calculating the Cohen's Kappa Statistics (19, 20). The process of the study 168 search decision will be guided by the PRISMA flow chart as demonstrated in figure 1 169 (16) to aid reporting of the scoping review. 170

171 iv. Charting the data

A data charting form as outlined in table 3, will be used to derive information from each
included study. Two independent reviewers will pilot test and modify the data charting
form.

175

 Table 3: Data charting form

Author & Year of publication
Journal
Aim of study
Study population
Study setting (rural and urban)
Study location (sub-Saharan Africa)
Study design

Main findings Other significant findings

176

177 v. Collating, summarising and reporting the results

Findings will be presented in two ways. Firstly, from numerical data on the incidence, prevalence and mortality of the study population will be reported. Secondly, we will produce tables and graphs based from thematic analysis that originate from the PCC to guide a summary of themes to extract from findings in relation to answering the study question.

183 vi. Appraisal of quality of evidence

The mixed method appraisal tool (MMAT) version 2018 will be utilized to appraise the 184 quality of empirical studies, these are primary research acquired from observation, 185 experimental or simulation of study methods i.e. quantitative, qualitative, and/or mixed 186 187 method studies (21). Appraisal of the included studies will be intended to assess the objectives of the study, method, study design, candidate recruitment, data collected, 188 analysis of data, discovered results, and authors' discussions and conclusions to 189 ensure they are reliable, trustworthy and valid. The appraisal process will involve two 190 independent reviewers assessing the checklist and criterion based on methodology 191 according to the MMAT (21). A percentage score will be calculated to evaluate the 192 quality of studies selected as follows: i) \leq 50%, will be low quality ii) 51–75%, will be 193 average guality and iii) 76–100%, will be considered as high guality. 194

195 vii. Ethical considerations

This scoping review involves synthesis of current evidence therefore ethical approval is not necessary. However, since the study is being conducted for degree purposes, ethical approval was sought. The study was ethically reviewed and approved submitted to the University of Pretoria Research Ethics Committee (Approval number: 606/2022).

201 **Discussion**

202 Screening of the cryptococcal antigen is the preferred approach for identifying risk of 203 progression to disease when managing people presenting with advanced HIV infection

(2). Screening for CrAg in PLHIV, followed by pre-emptive antifungal treatment for a
positive screening are one of the WHO's recommendations for prevention of
progression to CM (2). Highly accurate CrAg POC tests have been used for disease
screening to help expedite treatment (9, 11).

This scoping review will exclude studies conducted outside SSA as they will not be reflecting findings associated with the region of interest. Studies reporting evidence of patients receiving antifungal treatment will also be excluded as they will be giving evidence on people who have already been screened and not on the CrAg infection among PLHIV. Furthermore, review articles will be excluded on literature from primary studies conducted by other researchers. We anticipate that results of this scoping review will guide future policy and practice aimed on improving the HIV management.

215 Acknowledgement

The authors acknowledge the support received from the University of Pretoria during

the development of this protocol. The authors would also like to thank the library services for their assistance with optimising the search strategy.

219 Supporting material

220 S1 Figure 1: PRISMA-Scr flow chart

221 **References**

222 1. Tugume L, Rhein J, Hullsiek KH, Mpoza E, Kiggundu R, Ssebambulidde K, et al. HIV-Associated 223 Cryptococcal Meningitis Occurring at Relatively Higher CD4 Counts. J Infect Dis. 2019;219(6):877-83. 224 2. World Health Organization. Guidelines for the diagnosis, prevention, and management of 225 cryptococcal disease in HIV-infected adults, adolescents and children, March 2018: supplement to 226 the 2016 consolidated guidelines of the use of antiretroviral drugs for treating and preventing HIV 227 infection [Publications]. World Health Organization; 2018 [updated 2018. Available from: 228 https://apps.who.int/iris/handle/10665/260399.

- Longley N, Jarvis JN, Meintjes G, Boulle A, Cross A, Kelly N, et al. Cryptococcal Antigen
 Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study. Clin Infect Dis.
 2016;62(5):581-7.
- Li Y, Huang X, Chen H, Qin Y, Hou J, Li A, et al. The prevalence of cryptococcal antigen (CrAg)
 and benefits of pre-emptive antifungal treatment among HIV-infected persons with CD4+ T-cell
- counts < 200 cells/μL: evidence based on a meta-analysis. BMC Infect Dis. 2020;20(1):410.
 5. Ford N, Meintjes G, Vitoria M, Greene G, Chiller T. The evolving role of CD4 cell counts in HIV
 care. Curr Opin HIV AIDS. 2017;12(2):123-8.
- Ford N, Shubber Z, Jarvis JN, Chiller T, Greene G, Migone C, et al. CD4 Cell Count Threshold
- for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-
- analysis. Clin Infect Dis. 2018;66(suppl_2):S152-s9.

medRxiv preprint doi: https://doi.org/10.1101/2023.02.03.23285416; this version posted February 3, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

240 7. Otto SBJ, George PE, Mercedes R, Nabukeera-Barungi N. Cryptococcal meningitis and 241 immune reconstitution inflammatory syndrome in a pediatric patient with HIV after switching to 242 second line antiretroviral therapy: a case report. BMC Infect Dis. 2020;20(1):68. 243 8. Rajasingham R, Wake RM, Beyene T, Katende A, Letang E, Boulware DR. Cryptococcal 244 Meningitis Diagnostics and Screening in the Era of Point-of-Care Laboratory Testing. J Clin Microbiol. 245 2019;57(1). 246 9. Drain PK, Hong T, Krows M, Govere S, Thulare H, Wallis CL, et al. Validation of clinic-based 247 cryptococcal antigen lateral flow assay screening in HIV-infected adults in South Africa. Scientific 248 Reports. 2019;9(1):2687. Govender NP, Roy M, Mendes JF, Zulu TG, Chiller TM, Karstaedt AS. Evaluation of screening 249 10. 250 and treatment of cryptococcal antigenaemia among HIV-infected persons in Soweto, South Africa. 251 HIV Med. 2015;16(8):468-76. 252 11. Chukwuanukwu RC, Uchenna N, Mbagwu SI, Chukwuanukwu TO, Charles O. Cryptococcus 253 neoformans seropositivity and some haematological parameters in HIV seropositive subjects. Journal 254 of Infection and Public Health. 2020;13(7):1042-6. 255 12. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of 256 disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 257 2017;17(8):873-81. 258 13. National Institute for Communicable Disease. Cryptococcal antigen screening surveillance 259 report, South Africa, February 2017- July 2019 - Google Search 2022 [Available from: 260 https://www.google.com/search?g=Cryptococcal+antigen+screening+surveillance+report%2C+Sout h+Africa%2C+February+2017+%E2%80%93+July+2019&rlz=1C1CAFB enZA626ZA626&oq=Cryptococ 261 262 cal+antigen+screening+surveillance+report%2C+South+Africa%2C+February+2017+%E2%80%93+Jul 263 y+2019&aqs=chrome..69i57j69i59.1762438j0j4&sourceid=chrome&ie=UTF-8. 264 Arksey H, O'Malley L. Scoping studies: towards a methodological framework. International 14. 265 Journal of Social Research Methodology. 2005;8(1):19-32. 266 Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the methodology. Implement 15. 267 Sci. 2010;5(1):1-9. 268 16. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 269 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. 270 McGowan J, Straus S, Moher D, Langlois EV, O'Brien KK, Horsley T, et al. Reporting scoping 17. 271 reviews-PRISMA ScR extension. J Clin Epidemiol. 2020;123:177-9. 272 Warkentien T, Crum-Cianflone NF. An update on Cryptococcus among HIV-infected patients. 18. 273 Int J STD AIDS. 2010;21(10):679-84. 274 19. Hallgren KA. Computing Inter-Rater Reliability for Observational Data: An Overview and 275 Tutorial. Tutor Quant Methods Psychol. 2012;8(1):23-34. 276 20. Landis JR, Koch GG. The measurement of observer agreement for categorical data. 277 Biometrics. 1977;33(1):159-74.

- 278 21. Hong QN, Fabregues S, Bartlett G, Boardman F, Cargo M, Dagenais P, et al. The Mixed
- 279 Methods Appraisal Tool (MMAT) version 2018 for information professionals and researchers.
- 280 Education for Information. 2018;34(4):285-91.
- 281